

## SF36 survey

### 8 sub-scores

Table 32: Descriptive analysis of SF36 8 sub-scores (T-scores) at V1, V5 and V6 - ITT population

| <b>Visit</b>                     | <b>V1</b><br>N = 60 | <b>V5</b><br>N = 60 | <b>V6</b><br>N = 60 |
|----------------------------------|---------------------|---------------------|---------------------|
| <b>Physical Functioning (PF)</b> |                     |                     |                     |
| Treatment arm=Nintedanib         |                     |                     |                     |
| Mean (SD)                        | 46.36 ( 7.07)       | 46.26 ( 8.90)       | 47.55 ( 6.93)       |
| Median                           | 47.56               | 47.56               | 47.56               |
| Q1-Q3                            | 40.20 - 52.30       | 38.62 - 52.82       | 44.41 - 52.82       |
| Min-Max                          | 33.88 - 57.03       | 25.47 - 57.03       | 31.31 - 57.03       |
| N                                | 30                  | 30                  | 30                  |
| Treatment arm=Placebo            |                     |                     |                     |
| Mean (SD)                        | 46.09 ( 9.55)       | 48.55 ( 7.35)       | 45.28 (11.24)       |
| Median                           | 48.62               | 50.72               | 49.67               |
| Q1-Q3                            | 38.62 - 54.40       | 46.51 - 52.82       | 35.99 - 52.82       |
| Min-Max                          | 17.05 - 57.03       | 27.57 - 57.03       | 21.26 - 57.03       |
| N                                | 30                  | 29                  | 28                  |
| <b>Role-Physical (RP)</b>        |                     |                     |                     |
| Treatment arm=Nintedanib         |                     |                     |                     |
| Mean (SD)                        | 38.43 ( 9.66)       | 41.91 (10.88)       | 42.81 ( 9.90)       |
| Median                           | 37.26               | 42.16               | 40.93               |
| Q1-Q3                            | 34.81 - 42.16       | 32.36 - 49.51       | 37.26 - 51.96       |
| Min-Max                          | 20.12 - 56.85       | 17.67 - 56.85       | 27.46 - 56.85       |
| N                                | 30                  | 29                  | 30                  |
| Treatment arm=Placebo            |                     |                     |                     |
| Mean (SD)                        | 41.83 ( 9.34)       | 44.27 ( 9.23)       | 41.71 (10.35)       |
| Median                           | 42.16               | 44.61               | 42.16               |
| Q1-Q3                            | 37.26 - 47.06       | 37.26 - 51.96       | 36.04 - 49.51       |
| Min-Max                          | 20.12 - 56.85       | 25.02 - 56.85       | 17.67 - 56.85       |
| N                                | 30                  | 29                  | 27                  |
| <b>Bodily Pain (BP)</b>          |                     |                     |                     |
| Treatment arm=Nintedanib         |                     |                     |                     |
| Mean (SD)                        | 49.54 (10.46)       | 50.32 (10.39)       | 51.59 (10.32)       |
| Median                           | 48.38               | 50.49               | 52.61               |
| Q1-Q3                            | 43.10 - 61.06       | 40.19 - 62.12       | 41.78 - 62.12       |
| Min-Max                          | 25.14 - 62.12       | 29.36 - 62.12       | 33.59 - 62.12       |
| N                                | 30                  | 30                  | 30                  |

| <b>Visit</b>                    | <b>V1</b><br>N = 60 | <b>V5</b><br>N = 60 | <b>V6</b><br>N = 60 |
|---------------------------------|---------------------|---------------------|---------------------|
| <b>Treatment arm=Placebo</b>    |                     |                     |                     |
| Mean (SD)                       | 50.88 (11.23)       | 51.26 ( 8.94)       | 49.40 (10.89)       |
| Median                          | 57.36               | 52.61               | 47.85               |
| Q1-Q3                           | 43.10 - 62.12       | 44.15 - 57.89       | 44.15 - 62.12       |
| Min-Max                         | 29.36 - 62.12       | 29.36 - 62.12       | 24.08 - 62.12       |
| N                               | 30                  | 29                  | 28                  |
| <b>General Health (GH)</b>      |                     |                     |                     |
| <b>Treatment arm=Nintedanib</b> |                     |                     |                     |
| Mean (SD)                       | 40.06 ( 8.33)       | 41.21 (10.10)       | 40.72 (10.19)       |
| Median                          | 37.68               | 42.45               | 40.06               |
| Q1-Q3                           | 35.30 - 46.62       | 35.30 - 49.59       | 32.91 - 44.83       |
| Min-Max                         | 25.76 - 56.74       | 18.61 - 56.74       | 18.61 - 59.13       |
| N                               | 30                  | 29                  | 29                  |
| <b>Treatment arm=Placebo</b>    |                     |                     |                     |
| Mean (SD)                       | 40.28 ( 9.92)       | 41.97 ( 9.98)       | 40.36 ( 9.93)       |
| Median                          | 36.49               | 40.06               | 40.06               |
| Q1-Q3                           | 32.91 - 49.45       | 32.91 - 49.59       | 32.32 - 46.32       |
| Min-Max                         | 25.76 - 59.13       | 25.76 - 59.13       | 25.76 - 61.51       |
| N                               | 30                  | 29                  | 28                  |
| <b>Vitality (VT)</b>            |                     |                     |                     |
| <b>Treatment arm=Nintedanib</b> |                     |                     |                     |
| Mean (SD)                       | 45.95 ( 7.63)       | 48.65 (10.02)       | 48.76 ( 9.55)       |
| Median                          | 45.85               | 52.09               | 48.97               |
| Q1-Q3                           | 39.61 - 48.97       | 42.73 - 55.21       | 39.61 - 58.34       |
| Min-Max                         | 33.36 - 64.58       | 27.12 - 64.58       | 36.48 - 64.58       |
| N                               | 30                  | 29                  | 29                  |
| <b>Treatment arm=Placebo</b>    |                     |                     |                     |
| Mean (SD)                       | 47.72 ( 7.85)       | 51.55 ( 9.70)       | 48.53 (11.22)       |
| Median                          | 50.53               | 52.09               | 47.93               |
| Q1-Q3                           | 43.51 - 52.09       | 45.85 - 58.34       | 41.17 - 58.34       |
| Min-Max                         | 27.12 - 61.46       | 30.24 - 67.70       | 30.24 - 70.82       |
| N                               | 30                  | 29                  | 28                  |
| <b>Social Functioning (SF)</b>  |                     |                     |                     |
| <b>Treatment arm=Nintedanib</b> |                     |                     |                     |
| Mean (SD)                       | 41.03 (11.93)       | 43.58 (12.13)       | 45.40 (11.22)       |
| Median                          | 40.49               | 45.94               | 45.94               |
| Q1-Q3                           | 35.03 - 51.40       | 35.03 - 56.85       | 35.03 - 56.85       |
| Min-Max                         | 13.22 - 56.85       | 24.13 - 56.85       | 24.13 - 56.85       |
| N                               | 30                  | 30                  | 30                  |

| <b>Visit</b>                    | <b>V1</b><br>N = 60 | <b>V5</b><br>N = 60 | <b>V6</b><br>N = 60 |
|---------------------------------|---------------------|---------------------|---------------------|
| <b>Treatment arm=Placebo</b>    |                     |                     |                     |
| Mean (SD)                       | 41.40 ( 9.93)       | 47.07 (10.55)       | 42.44 (12.35)       |
| Median                          | 40.49               | 45.94               | 43.22               |
| Q1-Q3                           | 35.03 - 45.94       | 45.94 - 56.85       | 35.03 - 52.76       |
| Min-Max                         | 24.13 - 56.85       | 24.13 - 56.85       | 13.22 - 56.85       |
| N                               | 30                  | 29                  | 28                  |
| <b>Role-Emotional (RE)</b>      |                     |                     |                     |
| <b>Treatment arm=Nintedanib</b> |                     |                     |                     |
| Mean (SD)                       | 40.33 (12.33)       | 43.14 (13.54)       | 43.44 (12.39)       |
| Median                          | 38.39               | 48.10               | 44.22               |
| Q1-Q3                           | 32.56 - 53.93       | 32.56 - 55.88       | 32.56 - 55.88       |
| Min-Max                         | 17.01 - 55.88       | 9.24 - 55.88        | 20.90 - 55.88       |
| N                               | 30                  | 29                  | 30                  |
| <b>Treatment arm=Placebo</b>    |                     |                     |                     |
| Mean (SD)                       | 43.55 (12.12)       | 46.49 (10.36)       | 43.50 (11.41)       |
| Median                          | 44.22               | 48.10               | 44.22               |
| Q1-Q3                           | 32.56 - 55.88       | 40.33 - 55.88       | 36.44 - 55.88       |
| Min-Max                         | 17.01 - 55.88       | 20.90 - 55.88       | 13.12 - 55.88       |
| N                               | 29                  | 29                  | 27                  |
| <b>Mental Health (MH)</b>       |                     |                     |                     |
| <b>Treatment arm=Nintedanib</b> |                     |                     |                     |
| Mean (SD)                       | 46.19 ( 9.50)       | 46.15 (10.10)       | 46.12 ( 9.29)       |
| Median                          | 50.01               | 47.19               | 50.01               |
| Q1-Q3                           | 39.45 - 52.82       | 41.56 - 52.82       | 41.56 - 52.82       |
| Min-Max                         | 24.67 - 64.08       | 21.85 - 61.27       | 21.85 - 55.64       |
| N                               | 30                  | 29                  | 29                  |
| <b>Treatment arm=Placebo</b>    |                     |                     |                     |
| Mean (SD)                       | 47.75 ( 8.44)       | 48.55 ( 8.92)       | 47.29 (11.53)       |
| Median                          | 50.01               | 50.01               | 50.01               |
| Q1-Q3                           | 44.38 - 52.82       | 44.38 - 55.64       | 41.56 - 55.64       |
| Min-Max                         | 24.67 - 61.27       | 30.30 - 64.08       | 19.04 - 64.08       |
| N                               | 30                  | 29                  | 28                  |

Table 33: Relative change of SF36 8 sub-scores (T-scores) between V1-V5 and V1-V6 - ITT population

| <b>Treatment arm</b>                                  | <b>Nintedanib</b><br>N = 30 | <b>Placebo</b><br>N = 30 | <b>p-value</b>         |
|---|-----------------------------|--------------------------|------------------------|
| <b>Relative change of PF between V1 and V5 (//V1)</b> |                             |                          |                        |
| Mean (SD)   | 0.01 (0.18)                 | 0.08 (0.25)              | p=0.230 (Mann-Whitney) |
| 95% CI  | [-0.06, 0.07]               | [-0.01, 0.18]            |                        |
| Median  | 0.00                        | 0.00                     |                        |
| Q1-Q3   | -0.08 - 0.15                | -0.04 - 0.09             |                        |
| Min-Max   | -0.43 - 0.44                | -0.19 - 1.23             |                        |
| N   | 30                          | 29                       |                        |
| <b>Relative change of PF between V1 and V6 (//V1)</b> |                             |                          |                        |
| Mean (SD)   | 0.04 (0.15)                 | 0.01 (0.21)              | p=0.785 (Mann-Whitney) |
| 95% CI  | [-0.02, 0.09]               | [-0.07, 0.09]            |                        |
| Median  | 0.00                        | 0.00                     |                        |
| Q1-Q3   | -0.07 - 0.14                | -0.06 - 0.09             |                        |
| Min-Max   | -0.18 - 0.44                | -0.56 - 0.56             |                        |
| N   | 30                          | 28                       |                        |
| <b>Relative change of RP between V1 and V5 (//V1)</b> |                             |                          |                        |
| Mean (SD)   | 0.10 (0.25)                 | 0.08 (0.22)              | p=0.549 (Mann-Whitney) |
| 95% CI  | [0.01, 0.20]                | [-0.01, 0.16]            |                        |
| Median  | 0.09                        | 0.05                     |                        |
| Q1-Q3   | -0.07 - 0.26                | -0.06 - 0.12             |                        |
| Min-Max   | -0.36 - 0.76                | -0.23 - 0.71             |                        |
| N   | 29                          | 29                       |                        |
| <b>Relative change of RP between V1 and V6 (//V1)</b> |                             |                          |                        |
| Mean (SD)   | 0.15 (0.27)                 | 0.05 (0.26)              | p=0.182 (Mann-Whitney) |
| 95% CI  | [0.05, 0.25]                | [-0.05, 0.16]            |                        |
| Median  | 0.06                        | 0.00                     |                        |
| Q1-Q3   | -0.04 - 0.34                | -0.13 - 0.19             |                        |
| Min-Max   | -0.21 - 0.97                | -0.36 - 0.71             |                        |
| N   | 30                          | 27                       |                        |
| <b>Relative change of BP between V1 and V5 (//V1)</b> |                             |                          |                        |
| Mean (SD)   | 0.06 (0.31)                 | 0.04 (0.20)              | p=0.605 (Mann-Whitney) |
| 95% CI  | [-0.06, 0.18]               | [-0.04, 0.11]            |                        |
| Median  | 0.00                        | 0.00                     |                        |
| Q1-Q3   | -0.06 - 0.21                | -0.07 - 0.12             |                        |
| Min-Max   | -0.49 - 0.92                | -0.28 - 0.57             |                        |
| N   | 30                          | 29                       |                        |

| <b>Treatment arm</b>                           | <b>Nintedanib</b><br>N = 30 | <b>Placebo</b><br>N = 30 | <b>p-value</b>         |
|--|-----------------------------|--------------------------|------------------------|
| Relative change of BP between V1 and V6 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.08 (0.34)                 | 0.02 (0.29)              | p=0.388 (Mann-Whitney) |
| 95% CI   | [-0.05, 0.21]               | [-0.09, 0.13]            |                        |
| Median   | 0.00                        | 0.00                     |                        |
| Q1-Q3  | -0.07 - 0.15                | -0.16 - 0.08             |                        |
| Min-Max  | -0.29 - 1.47                | -0.43 - 1.12             |                        |
| N  | 30                          | 28                       |                        |
| Relative change of GH between V1 and V5 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.05 (0.23)                 | 0.05 (0.18)              | p=0.969 (Mann-Whitney) |
| 95% CI   | [-0.03, 0.14]               | [-0.02, 0.12]            |                        |
| Median   | 0.00                        | 0.00                     |                        |
| Q1-Q3  | -0.07 - 0.14                | -0.06 - 0.17             |                        |
| Min-Max  | -0.40 - 0.51                | -0.27 - 0.47             |                        |
| N  | 29                          | 29                       |                        |
| Relative change of GH between V1 and V6 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.03 (0.25)                 | 0.04 (0.18)              | p=0.817 (Mann-Whitney) |
| 95% CI   | [-0.06, 0.13]               | [-0.03, 0.11]            |                        |
| Median   | 0.00                        | 0.00                     |                        |
| Q1-Q3  | -0.15 - 0.14                | -0.07 - 0.10             |                        |
| Min-Max  | -0.34 - 0.61                | -0.29 - 0.51             |                        |
| N  | 29                          | 28                       |                        |
| Relative change of VT between V1 and V5 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.07 (0.22)                 | 0.10 (0.27)              | p=1.000 (Mann-Whitney) |
| 95% CI   | [-0.01, 0.16]               | [-0.00, 0.20]            |                        |
| Median   | 0.07                        | 0.06                     |                        |
| Q1-Q3  | -0.09 - 0.25                | -0.06 - 0.20             |                        |
| Min-Max  | -0.38 - 0.60                | -0.42 - 1.15             |                        |
| N  | 29                          | 29                       |                        |
| Relative change of VT between V1 and V6 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.08 (0.20)                 | 0.05 (0.32)              | p=0.310 (Mann-Whitney) |
| 95% CI   | [0.00, 0.16]                | [-0.07, 0.17]            |                        |
| Median   | 0.06                        | 0.00                     |                        |
| Q1-Q3  | -0.07 - 0.14                | -0.16 - 0.18             |                        |
| Min-Max  | -0.25 - 0.68                | -0.42 - 1.27             |                        |
| N  | 29                          | 28                       |                        |

| <b>Treatment arm</b>                           | <b>Nintedanib</b><br>N = 30 | <b>Placebo</b><br>N = 30 | <b>p-value</b>         |
|--|-----------------------------|--------------------------|------------------------|
| Relative change of SF between V1 and V5 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.10 (0.27)                 | 0.15 (0.25)              | p=0.391 (Mann-Whitney) |
| 95% CI   | [0.00, 0.20]                | [0.06, 0.24]             |                        |
| Median   | 0.00                        | 0.11                     |                        |
| Q1-Q3  | 0.00 - 0.21                 | 0.00 - 0.40              |                        |
| Min-Max  | -0.31 - 0.83                | -0.36 - 0.68             |                        |
| N  | 30                          | 29                       |                        |
| Relative change of SF between V1 and V6 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.18 (0.43)                 | 0.06 (0.30)              | p=0.414 (Mann-Whitney) |
| 95% CI   | [0.02, 0.34]                | [-0.05, 0.18]            |                        |
| Median   | 0.11                        | 0.00                     |                        |
| Q1-Q3  | 0.00 - 0.38                 | -0.11 - 0.16             |                        |
| Min-Max  | -0.31 - 2.06                | -0.55 - 0.74             |                        |
| N  | 30                          | 28                       |                        |
| Relative change of RE between V1 and V5 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.10 (0.31)                 | 0.08 (0.23)              | p=0.520 (Mann-Whitney) |
| 95% CI   | [-0.02, 0.21]               | [-0.01, 0.16]            |                        |
| Median   | 0.11                        | 0.00                     |                        |
| Q1-Q3  | 0.00 - 0.26                 | -0.09 - 0.23             |                        |
| Min-Max  | -0.63 - 0.72                | -0.26 - 0.72             |                        |
| N  | 29                          | 28                       |                        |
| Relative change of RE between V1 and V6 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.12 (0.29)                 | 0.07 (0.31)              | p=0.396 (Mann-Whitney) |
| 95% CI   | [0.01, 0.23]                | [-0.06, 0.19]            |                        |
| Median   | 0.00                        | 0.00                     |                        |
| Q1-Q3  | 0.00 - 0.26                 | -0.14 - 0.26             |                        |
| Min-Max  | -0.43 - 0.91                | -0.40 - 0.74             |                        |
| N  | 30                          | 27                       |                        |
| Relative change of MH between V1 and V5 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.01 (0.18)                 | 0.02 (0.17)              | p=0.875 (Mann-Whitney) |
| 95% CI   | [-0.05, 0.08]               | [-0.04, 0.09]            |                        |
| Median   | 0.00                        | 0.00                     |                        |
| Q1-Q3  | -0.05 - 0.06                | -0.07 - 0.07             |                        |
| Min-Max  | -0.53 - 0.43                | -0.34 - 0.46             |                        |
| N  | 29                          | 29                       |                        |

| <b>Treatment arm</b>                           | <b>Nintedanib</b><br>N = 30 | <b>Placebo</b><br>N = 30 | <b>p-value</b>         |
|--|-----------------------------|--------------------------|------------------------|
| Relative change of MH between V1 and V6 (//V1) |                             |                          |                        |
| Mean (SD)                                      | 0.02 (0.20)                 | 0.00 (0.19)              | p=0.719 (Mann-Whitney) |
| 95% CI   | [-0.06, 0.10]               | [-0.07, 0.07]            |                        |
| Median   | 0.00                        | 0.00                     |                        |
| Q1-Q3  | -0.09 - 0.11                | -0.10 - 0.10             |                        |
| Min-Max  | -0.39 - 0.51                | -0.47 - 0.36             |                        |
| N  | 29                          | 28                       |                        |

Figure 3: Spider graph of SF36 8 sub-scores (T-scores) at V1, V5 and V6 for Nintedanib group - ITT population







Figure 4: Spider graph of SF36 8 sub-scores (T-scores) at V1, V5 and V6 for Placebo group - ITT population



2 summary scores

Table 34: Descriptive analysis of SF36 summary scores (T-scores) at visit V1, V5 and V6 - ITT population

| <b>Visit</b>                       | <b>V1</b><br>N = 60 | <b>V5</b><br>N = 60 | <b>V6</b><br>N = 60 |
|------------------------------------|---------------------|---------------------|---------------------|
| <b>Physical Health Score (PHS)</b> |                     |                     |                     |
| Treatment arm=Nintedanib           |                     |                     |                     |
| Mean (SD)                          | 44.42 ( 7.14)       | 46.11 ( 7.85)       | 47.09 ( 6.50)       |
| Median                             | 43.99               | 45.85               | 46.25               |
| Q1-Q3                              | 40.66 - 48.75       | 40.83 - 52.52       | 43.61 - 48.68       |
| Min-Max                            | 30.15 - 57.04       | 26.01 - 57.93       | 37.98 - 60.00       |
| N                                  | 30                  | 28                  | 29                  |
| Treatment arm=Placebo              |                     |                     |                     |
| Mean (SD)                          | 44.83 ( 8.98)       | 46.83 ( 7.93)       | 44.10 ( 8.71)       |
| Median                             | 45.72               | 46.62               | 43.86               |
| Q1-Q3                              | 38.76 - 51.29       | 44.07 - 50.82       | 39.88 - 50.51       |
| Min-Max                            | 26.83 - 57.81       | 19.18 - 59.72       | 16.64 - 57.68       |
| N                                  | 29                  | 29                  | 27                  |
| <b>Mental Health Score (MHS)</b>   |                     |                     |                     |
| Treatment arm=Nintedanib           |                     |                     |                     |
| Mean (SD)                          | 43.05 (10.89)       | 44.66 (11.88)       | 45.05 (11.28)       |
| Median                             | 43.70               | 49.39               | 48.81               |
| Q1-Q3                              | 38.54 - 50.96       | 36.01 - 54.16       | 33.97 - 54.88       |
| Min-Max                            | 14.48 - 58.99       | 20.59 - 60.63       | 22.74 - 58.54       |
| N                                  | 30                  | 28                  | 29                  |
| Treatment arm=Placebo              |                     |                     |                     |
| Mean (SD)                          | 45.26 ( 9.58)       | 48.39 (10.10)       | 45.89 (12.07)       |
| Median                             | 48.87               | 50.00               | 46.98               |
| Q1-Q3                              | 39.62 - 51.77       | 42.00 - 55.81       | 38.43 - 55.33       |
| Min-Max                            | 19.76 - 61.65       | 26.90 - 64.26       | 18.95 - 64.71       |
| N                                  | 29                  | 29                  | 27                  |

Table 35: Relative change of SF36 summary scores (T-scores) between V1-V5 and V1-V6 - ITT population

| <b>Treatment arm</b>                                   | <b>Nintedanib</b><br>N = 30 | <b>Placebo</b><br>N = 30 | <b>p-value</b>         |
|--|-----------------------------|--------------------------|------------------------|
| <b>Relative change of PHS between V1 and V5 (//V1)</b> |                             |                          |                        |
| Mean (SD)  | 0.04 (0.17)                 | 0.06 (0.15)              | p=0.608 (Mann-Whitney) |
| 95% CI   | [-0.03, 0.11]               | [-0.00, 0.12]            |                        |
| Median   | 0.02                        | 0.02                     |                        |
| Q1-Q3  | -0.09 - 0.16                | -0.05 - 0.14             |                        |
| Min-Max  | -0.21 - 0.49                | -0.29 - 0.45             |                        |
| N  | 28                          | 28                       |                        |
| <b>Relative change of PHS between V1 and V6 (//V1)</b> |                             |                          |                        |
| Mean (SD)  | 0.07 (0.18)                 | 0.01 (0.15)              | p=0.246 (Mann-Whitney) |
| 95% CI   | [0.00, 0.14]                | [-0.05, 0.07]            |                        |
| Median   | 0.04                        | -0.02                    |                        |
| Q1-Q3  | -0.06 - 0.15                | -0.05 - 0.06             |                        |
| Min-Max  | -0.22 - 0.56                | -0.38 - 0.33             |                        |
| N  | 29                          | 27                       |                        |
| <b>Relative change of MHS between V1 and V5 (//V1)</b> |                             |                          |                        |
| Mean (SD)  | 0.08 (0.24)                 | 0.07 (0.22)              | p=0.643 (Mann-Whitney) |
| 95% CI   | [-0.02, 0.17]               | [-0.02, 0.16]            |                        |
| Median   | 0.10                        | 0.04                     |                        |
| Q1-Q3  | -0.02 - 0.17                | -0.04 - 0.19             |                        |
| Min-Max  | -0.43 - 0.76                | -0.41 - 0.81             |                        |
| N  | 28                          | 28                       |                        |
| <b>Relative change of MHS between V1 and V6 (//V1)</b> |                             |                          |                        |
| Mean (SD)  | 0.10 (0.35)                 | 0.05 (0.27)              | p=0.602 (Mann-Whitney) |
| 95% CI   | [-0.04, 0.23]               | [-0.06, 0.16]            |                        |
| Median   | 0.04                        | 0.03                     |                        |
| Q1-Q3  | -0.14 - 0.23                | -0.10 - 0.17             |                        |
| Min-Max  | -0.41 - 1.55                | -0.46 - 0.73             |                        |
| N  | 29                          | 27                       |                        |